ClinicalTrials.gg
TerminatedNCT02044822Updated Nov 19, 2018Results posted

Efficacy and Safety of Idelalisib in Combination With Rituximab in Patients With Previously Untreated Chronic Lymphocytic Leukemia With 17p Deletion

A Phase 2 interventional study of Idelalisib and Rituximab in B-cell Chronic Lymphocytic Leukemia (CLL) With 17p Deletion, sponsored by Gilead Sciences. Terminated at 56 sites in 14 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2018-11-19.

Sponsored by Gilead Sciences · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
102
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 25 studies testing idelalisib in Leukemia, Lymphocytic, Chronic, B-Cell — 1 open to participants now, 1 under way, none of them phase 3. idelalisib · Leukemia, Lymphocytic, Chronic, B-Cell.

Enrollment
13th of 25
102 · median 102
Started
2014
with 3 others
Phase 2
11 of 25
none open now
Registered
16th of 25
by date
Lead sponsor
19 of 25
Gilead Sciences

Among the 25 studies testing idelalisib in Leukemia, Lymphocytic, Chronic, B-Cell, this one is the 13th largest by enrollment, is one of 4 that started in 2014, is one of 11 in phase 2, and was the 16th registered.

Leukemia, Lymphocytic, Chronic, B-Cell

2,036 studies on the registry are indexed under Leukemia, Lymphocytic, Chronic, B-Cell; 237 are open to participants now.

Browse Leukemia, Lymphocytic, Chronic, B-Cell studies →

Open to participants now

1 of the 25 studies testing idelalisib in Leukemia, Lymphocytic, Chronic, B-Cell is open now, in 12 countries. Recruiting first, the newest first:

By country, each count listing its studies:

About idelalisib

idelalisib: first FDA approval 2014 (ZYDELIG), first EMA approval 2014. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 188 Leukemia, Lymphocytic, Chronic, B-Cell studies recruiting now, 150 (80%) set no upper age limit and 15 (8%) stop at 75 or younger; 17 take children under 18; 13 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 25 studies testing idelalisib in Leukemia, Lymphocytic, Chronic, B-Cell, or all of them as a file.
02

Study summary

The primary objective of this study is to evaluate overall response rate (ORR) following treatment with idelalisib plus rituximab in participants with previously untreated chronic lymphocytic leukemia (CLL) with 17p deletion.

An increased rate of deaths and serious adverse events (SAEs) among participants with front-line CLL and early-line indolent non-Hodgkin lymphoma (iNHL) treated with idelalisib in combination with standard therapies was observed by the independent data monitoring committee (DMC) during regular review of 3 Gilead Phase 3 studies. Gilead reviewed the unblinded data and terminated those studies in agreement with the DMC recommendation and in consultation with the US Food and Drug Administration (FDA). All front-line studies of idelalisib, including this study, were also terminated.

03

Conditions studied

  • B-cell Chronic Lymphocytic Leukemia (CLL) With 17p Deletion

Keywords

  • Chronic Lymphocytic Leukemia
  • CLL
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Key Inclusion Criteria:

  • Documented diagnosis of B-cell CLL, according to International Workshop on Chronic Lymphocytic Leukemia 2008
  • Presence of 17p deletion in CLL cells as demonstrated by fluorescence in-situ hybridization (FISH) testing
  • No prior therapy for CLL other than for disease complications
  • CLL that warrants treatment
  • Presence of measurable lymphadenopathy
  • (ECOG) performance status of ≤ 2

Key Exclusion Criteria:

  • Known histological transformation from CLL to an aggressive lymphoma (ie, Richter transformation)
  • Known presence of myelodysplastic syndrome
  • History of a non-CLL except for the following:

    • the malignancy has been in remission without treatment for ≥ 5 years prior to enrollment, or
    • carcinoma in situ of the cervix, or
    • adequately treated basal or squamous cell skin cancer or other localized non-melanoma skin cancer, or
    • asymptomatic prostate cancer without known disease and with no current requirement for therapy or requiring only hormonal therapy and with normal prostate specific antigen for ≥ 1 year prior to enrollment, or
    • ductal carcinoma in situ (DCIS) of the breast treated with lumpectomy alone, or
    • other adequately treated Stage 1 or 2 cancer currently in complete remission
  • Evidence of ongoing systemic bacterial, fungal, or viral infection at the time of enrollment
  • Ongoing liver injury
  • History of noninfectious pneumonitis
  • Ongoing inflammatory bowel disease
  • History of prior allogeneic bone marrow progenitor cell or solid organ transplantation
  • Ongoing therapy other than corticosteroids
  • Received last dose of study drug on another therapeutic clinical trial within 30 days prior to enrollment
  • Prior or ongoing illness, medical condition, surgical history, physical finding, (ECG) finding, or laboratory abnormality

Note: Other protocol defined Inclusion/Exclusion criteria may apply.

Terms in these criteria, in plain language(7)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
102 participants (actual)

Study arms

  • Experimental
    Idelalisib + rituximab

    Participants will receive rituximab for 8 weeks and Idelalisib continuously throughout the study (up to 10 years).

    Drug: Idelalisib · Drug: Rituximab

Interventions

  • 150 mg tablets administered orally twice daily

    Also known as: GS-1101, CAL-101, Zydelig®

  • 375 mg/m\^2 administered intravenously once weekly x 8 weeks

    Also known as: Rituxan

06

What researchers measure

Primary outcomes

  1. Overall Response Rate

    Overall response rate (ORR) was defined as the proportion of participants who achieve a confirmed complete or partial response. ORR was to be assessed by an independent review committee (IRC).

Secondary outcomes

  1. Duration of Response

    Duration of response (DOR) was defined as the interval from the first documentation of confirmed complete response or partial response (by IRC) to the first documentation of definitive disease progression or death from any cause. Definitive disease progression is chronic lymphocytic leukemia (CLL) progression based on standard criteria, excluding lymphocytosis alone.

  2. Nodal Response Rate

    Nodal response rate was defined as the proportion of participants who achieve a 50% decrease from baseline in the sum of the products of the greatest perpendicular diameters of index lesions. Nodal response rate was to be assessed by an IRC.

  3. Complete Response Rate

    Complete response rate was defined as the proportion of participants who achieve a confirmed complete response. Complete response rate was to be assessed by an IRC.

  4. Progression-Free Survival

    Progression-free survival (PFS) was defined as the interval from first dose of study drug to the first documentation of definitive disease progression or death from any cause. Definitive disease progression is CLL progression based on standard criteria, excluding lymphocytosis alone. PFS was to be assessed by an IRC.

  5. Overall Survival

    Overall survival was defined as the interval from the start of study treatment to death from any cause.

  6. Minimal Residual Disease Negativity Rate at Week 36

    Minimal residual disease (MRD) negativity rate was defined as the proportion of participants with MRD \< 10\^-4 assessed by flow cytometry in bone marrow at Week 36 after therapy initiation. For participants receiving the final dose of rituximab after the original scheduled date, the MRD assessment will be performed no fewer than 12 weeks after the last dose of rituximab.

07

Results

Posted May 11, 2017
Limitations and caveats
Due to the early termination of the study, efficacy data were not available for all participants, and therefore the prespecified analyses were not conducted.

Participant flow

Participants were enrolled at study sites in Australia, Europe, and the United States. The first participant was screened on 06 August 2014. The last study visit occurred on 17 May 2016.

Participant flow — Overall Study
MilestoneIdelalisib + Rituximab
Started102
Completed9
Not completed93
Withdrew: Study terminated by sponsor77
Withdrew: Investigator's discretion10
Withdrew: Withdrew consent3
Withdrew: Initiation of anti-neoplastic therapy2
Withdrew: Lost to follow-up1

Outcome measures

PrimaryOverall Response Rate

Overall response rate (ORR) was defined as the proportion of participants who achieve a confirmed complete or partial response. ORR was to be assessed by an independent review committee (IRC).

No measurements were reported for this outcome.

SecondaryDuration of Response

Duration of response (DOR) was defined as the interval from the first documentation of confirmed complete response or partial response (by IRC) to the first documentation of definitive disease progression or death from any cause. Definitive disease progression is chronic lymphocytic leukemia (CLL) progression based on standard criteria, excluding lymphocytosis alone.

No measurements were reported for this outcome.

SecondaryNodal Response Rate

Nodal response rate was defined as the proportion of participants who achieve a 50% decrease from baseline in the sum of the products of the greatest perpendicular diameters of index lesions. Nodal response rate was to be assessed by an IRC.

No measurements were reported for this outcome.

SecondaryComplete Response Rate

Complete response rate was defined as the proportion of participants who achieve a confirmed complete response. Complete response rate was to be assessed by an IRC.

No measurements were reported for this outcome.

SecondaryProgression-Free Survival

Progression-free survival (PFS) was defined as the interval from first dose of study drug to the first documentation of definitive disease progression or death from any cause. Definitive disease progression is CLL progression based on standard criteria, excluding lymphocytosis alone. PFS was to be assessed by an IRC.

No measurements were reported for this outcome.

SecondaryOverall Survival

Overall survival was defined as the interval from the start of study treatment to death from any cause.

No measurements were reported for this outcome.

SecondaryMinimal Residual Disease Negativity Rate at Week 36

Minimal residual disease (MRD) negativity rate was defined as the proportion of participants with MRD \< 10\^-4 assessed by flow cytometry in bone marrow at Week 36 after therapy initiation. For participants receiving the final dose of rituximab after the original scheduled date, the MRD assessment will be performed no fewer than 12 weeks after the last dose of rituximab.

No measurements were reported for this outcome.

Adverse events

Collected over Up to 17 months plus 30 days. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Idelalisib + Rituximab—46/102 (45.1%)98/102 (96.1%)
Most frequent serious events
Showing 10 of 76
Most frequent serious events
EventIdelalisib + Rituximab
PyrexiaGeneral disorders11/102
ColitisGastrointestinal disorders6/102
DiarrhoeaGastrointestinal disorders6/102
PneumoniaInfections and infestations5/102
Tumour lysis syndromeMetabolism and nutrition disorders4/102
Febrile neutropeniaBlood and lymphatic system disorders3/102
Atrial fibrillationCardiac disorders2/102
Lower respiratory tract infectionInfections and infestations2/102
Septic shockInfections and infestations2/102
Alanine aminotransferase increasedInvestigations2/102
Most frequent other events
Showing 10 of 41
Most frequent other events
EventIdelalisib + Rituximab
Alanine aminotransferase increasedInvestigations39/102
DiarrhoeaGastrointestinal disorders36/102
RashSkin and subcutaneous tissue disorders28/102
NeutropeniaBlood and lymphatic system disorders24/102
PyrexiaGeneral disorders24/102
Aspartate aminotransferase increasedInvestigations22/102
NauseaGastrointestinal disorders19/102
CoughRespiratory, thoracic and mediastinal disorders19/102
VomitingGastrointestinal disorders17/102
FatigueGeneral disorders16/102

Baseline characteristics

Intent-to-Treat (ITT) Analysis Set: participants who received at least 1 dose of study treatment

Age, Continuous
Age, Continuous(years)Idelalisib + Rituximab
Mean66 ± 9.9
Sex: Female, Male
Sex: Female, Male(Participants)Idelalisib + Rituximab
Female44
Male58
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)Idelalisib + Rituximab
Asian2
Black or African American2
White94
Not Permitted4
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)Idelalisib + Rituximab
Hispanic or Latino6
Not Hispanic or Latino91
Not Permitted5
Region of Enrollment
Region of Enrollment(participants)Idelalisib + Rituximab
Romania4
Hungary2
United States19
United Kingdom11
Portugal2
Spain7
Austria3
Czech Republic9
Belgium2
Denmark1
Poland15
Italy14
Australia6
France7
08

Study locations

56 sites
  • Arizona Oncology Associates, PC - HOPE
    Tucson, Arizona 85710, United States
  • Innovative Clinical Research Institute
    Whittier, California 90603, United States
  • Rocky Mountain Cancer Centers
    Boulder, Colorado 80303, United States
  • The University of Chicago Medicine
    Chicago, Illinois 60637, United States
  • Illinois Cancer Specialists
    Niles, Illinois 60714, United States
  • Washington University School of Medicine
    Saint Louis, Missouri 63110, United States
  • Duke University
    Durham, North Carolina 27705, United States
  • GHS Cancer Institute
    Greenville, North Carolina 29615, United States
  • Compass Oncology
    Portland, Oregon 97213, United States
  • Willamette Valley Cancer Center and Research Institute
    Springfield, Oregon 97477, United States
  • Hospital of the University of Pennsylvania, Abramson Cancer Center
    Philadelphia, Pennsylvania 19104, United States
  • St Vincent's Hospital, Sydney
    Darlinghurst, New South Wales 2010, Australia
  • St George Hospital
    Kogarah, New South Wales 2217, Australia
  • Icon Cancer Foundation
    South Brisbane, Queensland 4101, Australia
  • St Vincent's Hospital, Melbourne
    Fitzroy, Victoria 3065, Australia
  • Liverpool Hospital
    Liverpool, NSW 2170, Australia
  • Innsbruck University Hospital, Inner Medicine,
    Innsbruck, A-6020, Austria
  • Univ. Klinik für Innere Medizin III LKH
    Salzburg, 5020, Austria
  • Medizinische Universität Wien, Univ. Klinik f. Innere Med. I, Abteilung für Hämatologie und Hämostaseologie
    Vienna, 1090, Austria
  • AZ Sint-Jan AV Brugge-Oostende
    Brugge, 8000, Belgium
  • University Hospital Leuven
    Leuven, 3000, Belgium
  • University Hospital
    Brno, Czechia
  • Faculty Hospital Hradec Kralove
    Hradec Kralove, 500 05, Czechia
  • Hemato-Onkologicka Klinika Fn
    Olomuc, Czechia
  • Faculty hospital Ostrava
    Ostrava-Poruba, 70852, Czechia
  • Faculty Hospital Kralovske Vinohrady
    Prague 10, 10034, Czechia
  • Vseobecna Fakultim Nemocnice
    Praha, 12808, Czechia
  • Aalborg University Hospital
    Aalborg, 9100, Denmark
  • Centre Hospitalier Universitaire Hôpital Avicenne
    Bobigny, 93009, France
  • CHRU de Lille, Hopital Claude Huriez
    Lille, 59037, France
  • Centre Hospitalier Universitaire Nancy
    Nancy, 54511, France
  • Hopital Pitie-Salpetriere
    Paris cedex 13, 75651, France
  • University of Debrecen HSC Institute of internal Medicine, Department of Hematology
    Debrecen, 4032, Hungary
  • Institute of Hematology "L. e A. Seràgnoli"
    Bologna, 40138, Italy
  • A.O.Spedali Civili Brescia
    Brescia, 25123, Italy
  • A.O.Niguarda Ca' Granda
    Milan, 20162, Italy
  • Azienda Ospedaliero Universitaria Policlinico di Modena
    Modena, 41124, Italy
  • SCDU Medicina II ed Ematologia, A.O.U. San Luigi Gonzaga
    Orbassano, 10043, Italy
  • Uniwersyteckie Centrum Kliniczne
    Gdańsk, Pomorskie 80-952, Poland
  • Szpital Specjalistyczny w Brzozowie
    Brzozow, 36-200, Poland
  • Malopolskie Centrum Medyczne s.c.
    Krakow, 30-510, Poland
  • Wojewodzki Szpital Specjalistyczny
    Lodz, 93-510, Poland
  • Centrum Onkologii-Instytut Marii Sklodowskiej -Curie klinika Nowotworow Ukladu Chlonnego
    Warszawa, 02-781, Poland
  • Samodzielny Publiczny Szpital Kliniczny
    Wroclaw, 50-367, Poland
  • Centro Hospitalar De Lisboa Norte, E.P.E. - Hospital Santa Maria
    Lisbon, 1649-035, Portugal
  • IPO Porto Francisco Gentil, E.P.E
    Porto, 4200-072, Portugal
  • Emergency County Clinical Hospital Brasov
    Brasov, 500326, Romania
  • Spitalul Clinic Colentina
    Bucharest, 20125, Romania
  • Institutul Regional de Oncologie Iasi
    Iasi, 700348, Romania
  • Hospital Universitario Marques de Valdecilla
    Santander, Cantabria 39008, Spain
  • Hospital Clinic
    Barcelona, Cataluña 08036, Spain
  • Hospital Universitario Puerta De Hierro
    Madrid, 28222, Spain
  • Hospital Clinico Universitario De Valencia (Chuv)
    Valencia, 46010, Spain
  • Saint James's University Hospital
    Leeds, LS9 7TF, United Kingdom
  • Royal Liverpool & Broadgreen Univ. Hospitals
    Liverpool, L7 8XP, United Kingdom
  • University Hospital Southampton NHS Trust
    Southampton, 16, United Kingdom
09

References and documents

Individual participant data

Plan to share: Yes — Qualified external researchers may request IPD for this study after study completion. For more information, please visit our website at http://www.gilead.com/research/disclosure-and-transparency.

Supporting information: Study protocol, Statistical analysis plan

Time frame: 18 months after study completion

Access criteria: A secured external environment with username, password, and RSA code.

Data sharing details ↗ · www.gilead.com

No publications or documents are linked to this record.

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Aug 2014 to primary completion in Apr 2016, 20 months.

Results were first posted in May 2017, 1 year after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 22, 2014
First posted
Jan 24, 2014
StartActual
Aug 6, 2014
Primary completionActual
Apr 27, 2016
CompletionActual
May 17, 2016
Results first posted
May 11, 2017
Last update
Nov 19, 2018
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Nov 19, 2018, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT02044822
Lead sponsor
Gilead Sciences
Responsible party
Sponsor
First posted
Jan 24, 2014
Start date
Aug 6, 2014
Primary completion
Apr 27, 2016
Completion
May 17, 2016
Results posted
May 11, 2017
Last update
Nov 19, 2018

Study contacts

Gilead Study Director
study director · Gilead Sciences

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in Mar 2017. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Idelalisib · Rituximab

Start the discussion